{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-117567","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.865184+00:00","generated_at":"2026-05-30T09:47:39.124146+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Monte Rosa licenses VAV1 degrader MRT-6160 to Novartis for $150M upfront","bullets":["Novartis gets exclusive worldwide rights to develop, manufacture, and commercialize VAV1 MGDs including MRT-6160.","$150 million upfront payment; up to $2.1B in development, regulatory, and sales milestones starting at Phase 2.","Monte Rosa completes ongoing Phase 1 study; Novartis handles all subsequent development from Phase 2 onward.","Monte Rosa eligible for tiered royalties on ex-U.S. net sales and 30% U.S. profit/loss share from Phase 3 onward.","Deal validates Monte Rosa's QuEEN discovery engine and extends operational runway; closing subject to HSR clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-117567","json":"https://secwatch.observer/filing/0000950170-24-117567.json","markdown":"https://secwatch.observer/filing/0000950170-24-117567.md","text":"https://secwatch.observer/filing/0000950170-24-117567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024117567/0000950170-24-117567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024117567/glue-20241025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:47:39.124146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}